These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 7718586)
1. Crystal structure of cathepsin B inhibited with CA030 at 2.0-A resolution: A basis for the design of specific epoxysuccinyl inhibitors. Turk D; Podobnik M; Popovic T; Katunuma N; Bode W; Huber R; Turk V Biochemistry; 1995 Apr; 34(14):4791-7. PubMed ID: 7718586 [TBL] [Abstract][Full Text] [Related]
2. Quantitative evaluation of each catalytic subsite of cathepsin B for inhibitory activity based on inhibitory activity-binding mode relationship of epoxysuccinyl inhibitors by X-ray crystal structure analyses of complexes. Watanabe D; Yamamoto A; Tomoo K; Matsumoto K; Murata M; Kitamura K; Ishida T J Mol Biol; 2006 Oct; 362(5):979-93. PubMed ID: 16950396 [TBL] [Abstract][Full Text] [Related]
3. Crystal structure of the wild-type human procathepsin B at 2.5 A resolution reveals the native active site of a papain-like cysteine protease zymogen. Podobnik M; Kuhelj R; Turk V; Turk D J Mol Biol; 1997 Sep; 271(5):774-88. PubMed ID: 9299326 [TBL] [Abstract][Full Text] [Related]
4. Crystal structure of NS-134 in complex with bovine cathepsin B: a two-headed epoxysuccinyl inhibitor extends along the entire active-site cleft. Stern I; Schaschke N; Moroder L; Turk D Biochem J; 2004 Jul; 381(Pt 2):511-7. PubMed ID: 15084146 [TBL] [Abstract][Full Text] [Related]
5. Epoxysuccinyl dipeptides as selective inhibitors of cathepsin B. Gour-Salin BJ; Lachance P; Plouffe C; Storer AC; Ménard R J Med Chem; 1993 Mar; 36(6):720-5. PubMed ID: 8459399 [TBL] [Abstract][Full Text] [Related]
6. Structural basis for development of cathepsin B-specific noncovalent-type inhibitor: crystal structure of cathepsin B-E64c complex. Yamamoto A; Tomoo K; Matsugi K; Hara T; In Y; Murata M; Kitamura K; Ishida T Biochim Biophys Acta; 2002 Jun; 1597(2):244-51. PubMed ID: 12044902 [TBL] [Abstract][Full Text] [Related]
7. Molecular design of potent inhibitor specific for cathepsin B based on the tertiary structure prediction. Sumiya S; Yoneda T; Kitamura K; Murata M; Yokoo C; Tamai M; Yamamoto A; Inoue M; Ishida T Chem Pharm Bull (Tokyo); 1992 Feb; 40(2):299-303. PubMed ID: 1606628 [TBL] [Abstract][Full Text] [Related]
8. The refined 2.15 A X-ray crystal structure of human liver cathepsin B: the structural basis for its specificity. Musil D; Zucic D; Turk D; Engh RA; Mayr I; Huber R; Popovic T; Turk V; Towatari T; Katunuma N EMBO J; 1991 Sep; 10(9):2321-30. PubMed ID: 1868826 [TBL] [Abstract][Full Text] [Related]
9. Crystal structures of human procathepsin B at 3.2 and 3.3 Angstroms resolution reveal an interaction motif between a papain-like cysteine protease and its propeptide. Turk D; Podobnik M; Kuhelj R; Dolinar M; Turk V FEBS Lett; 1996 Apr; 384(3):211-4. PubMed ID: 8617355 [TBL] [Abstract][Full Text] [Related]
10. X-ray crystal structure of papain complexed with cathepsin B-specific covalent-type inhibitor: substrate specificity and inhibitory activity. Matsumoto K; Murata M; Sumiya S; Mizoue K; Kitamura K; Ishida T Biochim Biophys Acta; 1998 Mar; 1383(1):93-100. PubMed ID: 9546050 [TBL] [Abstract][Full Text] [Related]
11. Crystal structure of porcine cathepsin H determined at 2.1 A resolution: location of the mini-chain C-terminal carboxyl group defines cathepsin H aminopeptidase function. Guncar G; Podobnik M; Pungercar J; Strukelj B; Turk V; Turk D Structure; 1998 Jan; 6(1):51-61. PubMed ID: 9493267 [TBL] [Abstract][Full Text] [Related]
12. Design, Synthesis, and Structure-Activity Relationship Study of Epoxysuccinyl-Peptide Derivatives as Cathepsin B Inhibitors. Zhang X; Yang X; Wang H; Li S; Guo K; Jiang D; Xiao J; Liang D Biol Pharm Bull; 2017 Aug; 40(8):1240-1246. PubMed ID: 28502922 [TBL] [Abstract][Full Text] [Related]
13. pH Dependence of inhibitors targeting the occluding loop of cathepsin B. Cathers BE; Barrett C; Palmer JT; Rydzewski RM Bioorg Chem; 2002 Aug; 30(4):264-75. PubMed ID: 12392705 [TBL] [Abstract][Full Text] [Related]
14. E-64 analogues as inhibitors of cathepsin B. On the role of the absolute configuration of the epoxysuccinyl group. Schaschke N; Assfalg-Machleidt I; Machleidt W; Turk D; Moroder L Bioorg Med Chem; 1997 Sep; 5(9):1789-97. PubMed ID: 9354234 [TBL] [Abstract][Full Text] [Related]
15. Substrate/propeptide-derived endo-epoxysuccinyl peptides as highly potent and selective cathepsin B inhibitors. Schaschke N; Assfalg-Machleidt I; Machleidt W; Moroder L FEBS Lett; 1998 Jan; 421(1):80-2. PubMed ID: 9462845 [TBL] [Abstract][Full Text] [Related]
16. Inhibition mechanism of cathepsin L-specific inhibitors based on the crystal structure of papain-CLIK148 complex. Tsuge H; Nishimura T; Tada Y; Asao T; Turk D; Turk V; Katunuma N Biochem Biophys Res Commun; 1999 Dec; 266(2):411-6. PubMed ID: 10600517 [TBL] [Abstract][Full Text] [Related]
17. Expression and alteration of the S2 subsite of the Leishmania major cathepsin B-like cysteine protease. Chan VJ; Selzer PM; McKerrow JH; Sakanari JA Biochem J; 1999 May; 340 ( Pt 1)(Pt 1):113-7. PubMed ID: 10229665 [TBL] [Abstract][Full Text] [Related]
18. E-64c-hydrazide: a lead structure for the development of irreversible cathepsin C inhibitors. Radzey H; Rethmeier M; Klimpel D; Grundhuber M; Sommerhoff CP; Schaschke N ChemMedChem; 2013 Aug; 8(8):1314-21. PubMed ID: 23780739 [TBL] [Abstract][Full Text] [Related]
19. Binding mode of CA074, a specific irreversible inhibitor, to bovine cathepsin B as determined by X-ray crystal analysis of the complex. Yamamoto A; Hara T; Tomoo K; Ishida T; Fujii T; Hata Y; Murata M; Kitamura K J Biochem; 1997 May; 121(5):974-7. PubMed ID: 9192742 [TBL] [Abstract][Full Text] [Related]
20. The binding mode of an E-64 analog to the active site of cathepsin B. Feng MH; Chan SL; Xiang Y; Huber CP; Lim C Protein Eng; 1996 Nov; 9(11):977-86. PubMed ID: 8961350 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]